Delcath Systems, Inc. announced that new data from a retrospective study of Melphalan/HDS, entitled ‘Percutaneous Hepatic Perfusion For Unresectable Metastatic Ocular Melanoma To The Liver: A Multi-Institutional Report Of Outcomes,’ has been accepted for oral presentation at the Regional Cancer Therapies 12th International Symposium, taking place February 18 - 20, 2017 at the Snowbird Ski and Summer Resort in Snowbird, UT. The retrospective study was conducted by teams from Moffitt Cancer Center in Tampa, FL and the University of Southampton in the United Kingdom. The study explores patient treatment outcomes with Percutaneous Hepatic Perfusion (PHP Therapy) with Melphalan/HDS in patients with primary metastatic ocular melanoma with liver metastasis treated between 2008 and 2016. The study was led by Dr. Alexandra Gangi of the Moffitt Cancer Center.